Active Clinical Trials for Prostate Cancer


This page lists many active clinical trials (protocols) at Fox Chase Cancer Center for Prostate cancer. In addition to the title, some studies below have brief summaries.

Clinical trials, or protocols, are research studies conducted with people who volunteer to take part. You benefit by having access to new cancer treatments and options not otherwise available, in addition to the excellent care offered at Fox Chase.

For more information on clinical trials at Fox Chase Cancer Center, or to find a study, call 1-888 FOX CHASE (1-888-369-2427).
Open DateTrial NumberPrincipal InvestigatorTitle
09/18/2003IRB03835/03-835Eric Horwitz Prospective Collection Of Characteristics And Outcome Of Patients Treated For Prostate Cancer At Fox Chase Cancer Center
02/27/2012IRB11825/11-825Suzanne Miller Randomized Controlled Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS - PRostate Cancer Online Guide & Resources for Electronic Survivorship Service)
11/19/1996IRB96091/96-091Elias Obeid Prostate Cancer Risk Assessment Program
11/11/2015PSOTIO001/13-056Matthew Zibelman A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
12/10/2013IRB13846/13-846Elias Obeid Genetic Evaluation Of Men - The GEM Registry
08/04/201414-036/14-036Nestor Esnaola A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-Based, Protocol-Driven Management in Patients Undergoing Major Cancer Surgery
01/13/2015C28002/14-054Anthony Olszanski A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination with MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan in Adult Patients with Advanced Nonhematologic Malignancies
01/14/200908854/08-854Elias Obeid The role of genetic variants at chromosomal loci 8q and 17q in prostate cancer screening in African American men and men with a family history of prostate cancer
09/01/201615-1009/15-1009Anthony Olszanski A Phase I Dose-Escalation Study of ONC201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
05/15/201515-9018/15-9018Marc Smaldone Pennsylvania Urologic Regional Collaborative
10/28/201515-7002/15-7002Lori Goldstein Molecular Analysis for Therapy Choice (MATCH)
10/26/201616-1056/16-1056Namrata Vijayvergia A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients with Metastatic High Grade Neuroendocrine Tumors
07/11/201616-8002/16-8002Michael Hall Association of Baseline Nutritional Status with Toxicity and Outcomes in Early Phase Trial Participants
01/13/201716-1043/16-1043Alexander Kutikov REASSURE ME
01/16/201716-2004/16-2004Matthew Philp Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction
05/16/201716-1060/16-1060Philip Pancari A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)
10/05/201716-1062/16-1062Anthony Olszanski A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors
02/10/201716-1074/16-1074David Chen A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS)
06/21/201716-1071/16-1071Anthony Olszanski A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination with Anticancer Agents in Subjects with Selected Advanced Solid Tumors
01/05/201716-1073/16-1073Anthony Olszanski Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors
05/06/201615-1081/15-1081Wafik El-Deiry A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
12/01/201515-1015/15-1015Daniel Geynisman Bicalutamide with or without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)
07/28/201515-9022/15-9022Eric Horwitz Short term complications in prostate brachytherapy, active surveillance, and prostatectomy.
06/23/201717-1008/17-1008Daniel Geynisman A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, Relative to Placebo plus Abiraterone plus Prenisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
11/16/201717-2003/17-2003Mark Sobczak Phase II/III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel